1,084 results on '"Penault-Llorca, F."'
Search Results
2. Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023
3. Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe
4. Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer
5. Le ganglion sentinelle : point de vue du pathologiste avec un focus sur l'expérience dans le cancer du sein
6. European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer
7. Refining patient selection for breast cancer immunotherapy: beyond PD-L1
8. Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in France
9. ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research
10. Clinical and molecular practice of European thoracic pathology laboratories during the COVID-19 pandemic. The past and the near future
11. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
12. Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network
13. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration
14. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
15. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer
16. Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer
17. Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer
18. A phase Ib dose allocation study of oral administration of lucitanib given in combination with fulvestrant in patients with estrogen receptor-positive and FGFR1-amplified or non-amplified metastatic breast cancer
19. 20P Spatial analysis of residual tumor tissue provides new clues for post-neoadjuvant treatment approaches in triple-negative breast cancer
20. SA 8.1 Assessing HER2 heterogeneity
21. Networking for ovarian rare tumors: a significant breakthrough improving disease management
22. 3rd ESO–ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3)
23. Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study
24. Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer
25. Understanding the current use of breast cancer multigene signatures in clinical practice across Europe: global results from the PROCURE Project
26. Classification et signatures moléculaires des cancers du sein en 2017
27. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
28. 164P Current use of breast cancer multigene signatures in clinical practice among European experts: Results from the PROCURE Project
29. Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact
30. Present and future breast cancer management—bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industry
31. Characteristics and clinical outcome of T1 breast cancer: a multicenter retrospective cohort study
32. 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
33. Tu-be or not tu-be: That is the question… About serous ovarian carcinogenesis
34. Potential histological discordance revealed by second review in the national rare gynecological cancer network (TMRG)
35. 35P European consensus on the utility of breast cancer multigene signatures in routine clinical practice: PROCURE project final results
36. FOXP3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the phase III UNICANCER-PACS 01 trial
37. Triple negative breast cancer: Proposals for a pragmatic definition and implications for patient management and trial design
38. Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy
39. Autologous Fibroblasts as Potential Vehicle for Regional Ovarian Cancer Gene Therapy
40. γ-Interferon Gene Transfer as a Therapeutic Strategy for Ovarian Cancer
41. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group
42. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
43. Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer
44. Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts
45. 159P SiMosein, a real-life prospective evaluation of EndoPredict use in early ER-positive, HER2-negative breast cancers
46. 444P Prevalence of NTRK1/2/3 fusions in dMMR/MSI metastatic colorectal cancer
47. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
48. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†
49. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
50. A nomogram predictive of non-sentinel lymph node involvement in breast cancer patients with a sentinel lymph node micrometastasis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.